Akero Therapeutics, Inc.
AKRODelisted Dec 9, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001744659
Akero Therapeutics, Inc. was delisted on Dec 9, 2025; its insiders filed their last Form 4 on Dec 9, 2025; 265 institutions reported holding it in 13F filings for Q3 2025, worth $4.34B in total; no superinvestor held it.
Q2 2024 vs. Q1 2024
How the institutions holding Akero Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Of which not filed for Q2 2024 | Q2 2024 | Change |
|---|---|---|---|---|
| Holders | 173 | 3 | 153 | −17 |
| Shares | 73.1M | 50.6K | 71.8M | −1.25M (−1.7%) |
| Value | $1.85B | $1.28M | $1.68B | −$160.9M (−8.7%) |
3 institutions that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Akero Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Braidwell LP | 1,084,400 | $25.4M | 0.80% |
| Rheos Capital Works Inc. | 216,000 | $5.07M | 0.27% |
| Voloridge Investment Management, LLC | 193,836 | $4.55M | 0.02% |
| Corebridge Financial, Inc. | 36,473 | $855.7K | 0.00% |
| Mirae Asset Global ETFs Holdings Ltd. | 35,469 | $831.8K | 0.00% |
| Trexquant Investment LP | 24,651 | $578.3K | 0.01% |
| Renaissance Technologies LLC | 24,100 | $565.4K | 0.00% |
| Two Sigma Advisers, LP | 18,100 | $424.6K | 0.00% |
| American Century Companies Inc | 14,811 | $347.5K | 0.00% |
| Graham Capital Management, L.P. | 10,897 | $255.6K | 0.01% |
| Brevan Howard Capital Management LP | 10,191 | $239.1K | 0.02% |
| ExodusPoint Capital Management, LP | 9,930 | $233.0K | 0.00% |
| Verition Fund Management LLC | 9,256 | $217.1K | 0.00% |
| EntryPoint Capital, LLC | 4,311 | $101.1K | 0.05% |
| Whittier Trust Co | 157 | $3.68K | 0.00% |
| Harbour Investments, Inc. | 30 | $704 | 0.00% |
| GWM Advisors LLC | 7 | $164 | 0.00% |
Sold out (34)
Institutions that held Akero Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
Not filed for Q2 2024 yet (3)
Institutions that held Akero Therapeutics, Inc. at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Credit Suisse AG | 46,547 | $1.18M |
| Cambridge Trust Co | 3,500 | $88.4K |
| Cutler Group LP | 600 | $15.0K |